SCD & TDT Research Innovation Awards
SCD & TDT Research Innovation Awards support emerging M.D. and Ph.D. researchers through mentored projects to advance understanding of sickle cell disease and transfusion-dependent beta thalassemia.
Funder: Vertex Pharmaceuticals
Due Dates: 2026 cycle (accepting applications; deadline not stated)
Funding Amounts: Up to $125,000 USD over two years; up to three awards annually
Summary: Mentored research awards support emerging M.D. and Ph.D. researchers advancing understanding of sickle cell disease and transfusion-dependent beta thalassemia.
Key Information: Projects must be mentored by established SCD and TDT researchers.
Description
Vertex Pharmaceuticals’ SCD & TDT Research Innovation Awards are competitive grants supporting the next generation of M.D.s and Ph.D.s as they establish careers in hematology research. The program focuses on advancing understanding of hemoglobinopathies, specifically sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
The program offers Mentored RIAs for projects conducted with established SCD and TDT researchers, placing mentorship alongside scientific investigation. It forms part of Vertex’s broader support for scientific research, innovation, and initiatives that advance knowledge and care for people living with serious diseases in its research focus areas. An independent steering committee reviews applications and selects award recipients.
